150 related articles for article (PubMed ID: 16140485)
21. The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific.
Elmes NJ; Nasveld PE; Kitchener SJ; Kocisko DA; Edstein MD
Trans R Soc Trop Med Hyg; 2008 Nov; 102(11):1095-101. PubMed ID: 18541280
[TBL] [Abstract][Full Text] [Related]
22. Development of SMEDDS using natural lipophile: application to beta-Artemether delivery.
Mandawgade SD; Sharma S; Pathak S; Patravale VB
Int J Pharm; 2008 Oct; 362(1-2):179-83. PubMed ID: 18652886
[TBL] [Abstract][Full Text] [Related]
23. Lack of sex effect on the pharmacokinetics of primaquine.
Elmes NJ; Bennett SM; Abdalla H; Carthew TL; Edstein MD
Am J Trop Med Hyg; 2006 Jun; 74(6):951-2. PubMed ID: 16760502
[TBL] [Abstract][Full Text] [Related]
24. Dipeptide derivatives of primaquine as transmission-blocking antimalarials: effect of aliphatic side-chain acylation on the gametocytocidal activity and on the formation of carboxyprimaquine in rat liver homogenates.
Portela MJ; Moreira R; Valente E; Constantino L; Iley J; Pinto J; Rosa R; Cravo P; do Rosário VE
Pharm Res; 1999 Jun; 16(6):949-55. PubMed ID: 10397619
[TBL] [Abstract][Full Text] [Related]
25. Enantioselective pharmacokinetics of primaquine in healthy human volunteers.
Tekwani BL; Avula B; Sahu R; Chaurasiya ND; Khan SI; Jain S; Fasinu PS; Herath HM; Stanford D; Nanayakkara NP; McChesney JD; Yates TW; ElSohly MA; Khan IA; Walker LA
Drug Metab Dispos; 2015 Apr; 43(4):571-7. PubMed ID: 25637634
[TBL] [Abstract][Full Text] [Related]
26. A nanometer lipid emulsion, lipid nano-sphere (LNS), as a parenteral drug carrier for passive drug targeting.
Seki J; Sonoke S; Saheki A; Fukui H; Sasaki H; Mayumi T
Int J Pharm; 2004 Apr; 273(1-2):75-83. PubMed ID: 15010132
[TBL] [Abstract][Full Text] [Related]
27. Primaquine-induced differential gene expression analysis in mice liver using DNA microarrays.
Noel S; Sharma S; Shanker R; Rath SK
Toxicology; 2007 Sep; 239(1-2):96-107. PubMed ID: 17686563
[TBL] [Abstract][Full Text] [Related]
28. Characterization, in vitro and in vivo studies on primaquine diphosphate liposomes.
Arica B; Ozer AY; Ercan MT; Hincal AA
J Microencapsul; 1995; 12(5):469-85. PubMed ID: 8544091
[TBL] [Abstract][Full Text] [Related]
29. Imported non-Plasmodium falciparum malaria: a five-year prospective study in a European referral center.
Bottieau E; Clerinx J; Van Den Enden E; Van Esbroeck M; Colebunders R; Van Gompel A; Van Den Ende J
Am J Trop Med Hyg; 2006 Jul; 75(1):133-8. PubMed ID: 16837719
[TBL] [Abstract][Full Text] [Related]
30. Establishment of an in vitro assay for assessing the effects of drugs on the liver stages of Plasmodium vivax malaria.
Chattopadhyay R; Velmurugan S; Chakiath C; Andrews Donkor L; Milhous W; Barnwell JW; Collins WE; Hoffman SL
PLoS One; 2010 Dec; 5(12):e14275. PubMed ID: 21151554
[TBL] [Abstract][Full Text] [Related]
31. Effects of an NADPH-generating system on primaquine degradation by hamster liver fractions.
Abu-El-Haj S; Allahyari R; Chavez E; Fraser IM; Strother A
Xenobiotica; 1988 Oct; 18(10):1165-78. PubMed ID: 3242312
[TBL] [Abstract][Full Text] [Related]
32. Differential kinetic profiles and metabolism of primaquine enantiomers by human hepatocytes.
Fasinu PS; Avula B; Tekwani BL; Nanayakkara NP; Wang YH; Bandara Herath HM; McChesney JD; Reichard GA; Marcsisin SR; Elsohly MA; Khan SI; Khan IA; Walker LA
Malar J; 2016 Apr; 15():224. PubMed ID: 27093859
[TBL] [Abstract][Full Text] [Related]
33. Do apoptotic Plasmodium-infected hepatocytes initiate protective immune responses?
Renia L; Maranon C; Hosmalin A; Gruner AC; Silvie O; Snounou G
J Infect Dis; 2006 Jan; 193(1):163-4; author reply 164-5. PubMed ID: 16323145
[No Abstract] [Full Text] [Related]
34. Pulmonary edema due to Plasmodium vivax malaria in an American missionary.
Illamperuma C; Allen BL
Infection; 2007 Oct; 35(5):374-6. PubMed ID: 17721740
[TBL] [Abstract][Full Text] [Related]
35. The metabolism of primaquine to its active metabolite is dependent on CYP 2D6.
Pybus BS; Marcsisin SR; Jin X; Deye G; Sousa JC; Li Q; Caridha D; Zeng Q; Reichard GA; Ockenhouse C; Bennett J; Walker LA; Ohrt C; Melendez V
Malar J; 2013 Jun; 12():212. PubMed ID: 23782898
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the safety and tolerability of a short higher-dose primaquine regimen for presumptive anti-relapse therapy in healthy subjects.
Ebringer A; Heathcote G; Baker J; Waller M; Shanks GD; Edstein MD
Trans R Soc Trop Med Hyg; 2011 Oct; 105(10):568-73. PubMed ID: 21890160
[TBL] [Abstract][Full Text] [Related]
37. Photoreactivity of biologically active compounds, XIV: influence of oxygen on light induced reactions of primaquine.
Kristensen S; Nord K; Orsteen AL; Tønnesen HH
Pharmazie; 1998 Feb; 53(2):98-103. PubMed ID: 9540107
[TBL] [Abstract][Full Text] [Related]
38. Atypical Plasmodium vivax malaria in a traveler: bilateral hydronephrosis, severe thrombocytopenia, and hypotension.
Rifakis PM; Hernandez O; Fernández CT; Rodriguez-Morales AJ; Von A; Franco-Paredes C
J Travel Med; 2008; 15(2):119-21. PubMed ID: 18346245
[TBL] [Abstract][Full Text] [Related]
39. Regional differences in the response of Plasmodium vivax malaria to primaquine as anti-relapse therapy.
Goller JL; Jolley D; Ringwald P; Biggs BA
Am J Trop Med Hyg; 2007 Feb; 76(2):203-7. PubMed ID: 17297026
[TBL] [Abstract][Full Text] [Related]
40. [New use of primaquine for malaria].
Oliver M; Simon F; de Monbrison F; Beavogui AH; Pradines B; Ragot C; Moalic JL; Rapp C; Picot S
Med Mal Infect; 2008 Apr; 38(4):169-79. PubMed ID: 18395381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
